US5015751044 - Common Stock
KYMERA THERAPEUTICS INC
NASDAQ:KYMR (5/6/2024, 7:11:13 PM)
After market: 38.3 0 (0%)38.3
+0.9 (+2.41%)
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling and Quantitative System Pharmacology Model. The Company’s clinical-stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). The Company’s programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
KYMERA THERAPEUTICS INC
200 Arsenal Yards Blvd., Suite 230
Watertown MASSACHUSETTS 02139
P: 18572855314
CEO: Nello Mainolfi
Employees: 192
Website: https://www.kymeratx.com/
KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase...
Here you can normally see the latest stock twits on KYMR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: